Roth Capital Remains a Buy on Aridis Pharmaceuticals (ARDS)

In a report issued on October 19, Jonathan Aschoff from Roth Capital maintained a Buy rating on Aridis Pharmaceuticals (ARDSResearch Report), with a price target of $18.00. The company’s shares closed last Thursday at $7.01.

According to TipRanks.com, Aschoff has 0 stars on 0-5 stars ranking scale with an average return of -2.2% and a 40.8% success rate. Aschoff covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Inovio Pharmaceuticals, and Cellectar Biosciences.

Currently, the analyst consensus on Aridis Pharmaceuticals is a Moderate Buy with an average price target of $20.00, a 179.3% upside from current levels. In a report issued on October 19, Maxim Group also assigned a Buy rating to the stock with a $17.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $10.18 and a one-year low of $3.80. Currently, Aridis Pharmaceuticals has an average volume of 11.94K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.